Soluble receptor for urokinase plasminogen activator in both full- length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3294-3298

  Wahlberg, Karin ^a   Høyer Hansen, Gunilla ^b   Casslén, Bertil ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; ASCITES FLUID ANALYSIS; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MIDDLE AGED; OVARIAN CYSTS; OVARIAN NEOPLASMS; PRECANCEROUS CONDITIONS; RECEPTORS, CELL SURFACE; SOLUBILITY;

EID: 0032146117     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Andreasen, P. A., Kjøller, L., Christensen, L., and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22, 1997.
2. Wei, Y., Waltz, D. A., Rao, N., Drummond, R. J., Rosenberg, S., and Chapman, H. A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem., 269: 32380-32388, 1994.
3. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., and Chapman, H. A. Regulation of integrin function by the urokinase receptor. Science (Washington DC), 273: 1551-1555, 1996.
4. Kanse, S. M., Kost, C., Wilhelm, O. Q., Andreasen, P. A., and Preissner, K. T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res., 244: 344-353, 1996.
5. Høyer-Hansen, G., Behrendt, N., Ploug, M., Danø, K., and Preissner, K. T. The intact receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett., 420: 79-85, 1997.
6. Stoppelli M., Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Assoian, R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA, 82: 4939-4943, 1985.
7. r 55,000 form of the human plasminogen activator, urokinase. J. Cell. Biol., 100: 86-92, 1985.
8. Pyke, C., Kristensen, P., and Ralfkiaer, E. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol., 138: 1059-1067, 1991.
9. Ganesh, S., Sier, C. F. M., Heerding, M. M., Griffoen, G., Lamers, C. B. H. W., and Verspaget, H. W. Urokinase receptor and colorectal cancer survival. Lancet, 344: 401-402, 1994.
10. Pyke, C., Graem, N., Ralfkiaer, E., Rønne, E., Høyer-Hansen, G., Brünner, N., and Danø, K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res., 53: 1911-1915, 1993.
11. Rønne, E., Høyer-Hansen, G., Brünner, N., Pedersen, H., Rank, F., Osborne, C. K., Clark, G. M., Danø, K., and Grøndahl-Hansen, J. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res. Treat., 33: 199-207, 1995.
12. Pedersen, H., Brünner, N., Francis, D., Österlind, K., Rønne, E., Høi Hansen, H., Danø, K., and Grøndahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
13. Casslén, B., Gustavsson, B., and Åstedt, B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur. J. Cancer, 27: 1445-1448, 1991.
14. Rønne, E., Pappot, H., Grøndahl-Hansen, J., Høyer-Hansen, G., Plesner, T., Hansen, N. E., and Danø, K. The receptors for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal hemoglobinuria. Br. J. Haematol., 89: 576-581, 1995.
15. Stephens, R. W., Pedersen, A. N., Nielsen, H. J., Hamers, M. J. A. G., Høyer-Hansen, G., Rønne, E., Dybj[se]r, E., Danø, K., and Brünner, N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin. Chem., 43: 1868-1876, 1997.
16. Pedersen, N., Schmitt, M., Rønne, E., Nicoletti, M. I., Høyer-Hansen, G., Conese, M., Giavazzi, R., Danø, K., Kuhn, W., Janicke, F., and Blasi, F. A. Ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J. Clin. Invest., 92: 2160-2167, 1993.
17. Behrendt N., Rønne, E., Ploug, M., Petri, T., Løber, D., Nielsen, L. S., Schleunning, W-D., Blasi, F., Appella, E., and Danø, K. The human receptor for urokinase plasminogen activator. J. Biol. Chem., 265: 6453-6460, 1990.
18. Ploug, M., Behrendt, N., Løber, D., and Danø, K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Thromb. Haemostasis, 17: 183-193, 1991.
19. Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Danø, K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem., 266: 7842-7847, 1991.
20. 2-terminal domain of the urokinase receptor. FEBS Lett., 288: 233-236, 1991.
21. Høyer-Hansen, G., Rønne, E., Solberg, H., Behrendt, N., Ploug, M., Lund, L. R., Ellis, V., and Danø, K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem., 267: 18224-18229, 1992.
22. Høyer-Hansen, G., Ploug, M., Behrendt, N., Rønne, E., and Danø, K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur. J. Biochem., 243: 21-26, 1997.
23. Mazzieri, R., Høyer-Hansen, G., Rønne, E., Løber, D., Vagnarelli, P., Raimondi, E., De Carli, L., Danø, K., and Mignatti, P. Urokinase and urokinase receptor expression in somatic cell hybrids. Fibrinolysis, 8: 344-352, 1994.
24. Solberg, H., Rømer, J., Brünner, N., Holm, A., Sidenius, N., Danø, K., and Høyer-Hansen, G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer, 58: 877-881, 1994.
25. Pettersson, F. Annual Report on the Results of Treatment in Gynecological Cancer, pp. 1-277. Stockholm: International Federation of Gynecology and Obstetrics, 1995.
26. Rønne, E., Behrendt, N., Ploug, M., Nielsen, H. J., Wöllisch, E., Weidle, U., Danø, K., and Høyer-Hansen, G. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J. Immunol. Methods, 167: 91-101, 1994.
27. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
28. Wilhelm, O., Wilhelm, S., Escott, G., and Brünner, G. A cellular GPI-specific phospholipase D regulates the biological function of the urokinase receptor. Fibrinolysis Proteolysis, 11 (Suppl. 3): 36, 1997.
29. Casslén, B., Bossmar, T., Lecander, I., and Åstedt, B. Plasminogen activator and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur. J. Cancer, 30A: 1302-1309, 1994.
30. Jacobs, I. J., and Bast, R. C. The CA-125 tumor associated antigen: a review of the literature. Hum. Reprod., 4: 1-12, 1989.
31. Cohen, C. J., and Jennings, T. S. Screening for ovarian cancer: the role of noninvasive imaging techniques. Am. J. Obstet. Gynecol., 170: 1088-1094, 1994.
32. Høyer-Hansen, G., Solberg, H., Rønne, E., Behrendt, N., and Danø, K. Variants of the receptor for urokinase-type plasminogen activator. In: K. T. Preissner, E. Rosenblatt, C. Kost, J. Wegerhoff, and D. Mosher (eds.), Biology of Vitronectin and Their Receptors, pp. 289-294. Amsterdam: Elsevier Science Publishers, 1993.
33. Pujade-Lauraine, E., Lu, H., Mirshahi, S., Soria, J., Soria, C., Bernadou, A., Kruithof, E. K. O., Lijner, H. R., and Burtin, P. The plasminogen-activation system in ovarian tumors. Int. J. Cancer, 55: 27-31, 1993.